2023-504187-42-00招募中1 期
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 52
- 试验地点
- 9
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (9)
Loading locations...
相似试验
招募中
1 期
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75
招募中
1 期
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer2023-504063-17-00Janssen - Cilag International48
招募中
1 期
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.2025-521407-52-00Janssen Cilag International120
招募中
1 期
First-in-Human Study of RO78126532025-522101-37-00F. Hoffmann-La Roche AG12
招募中
1 期
A Phase 1 study of JNJ-87704916, a tumor-targeting virus, injected into tumor for advanced cancer2023-506495-27-00Johnson And Johnson Enterprise Innovation Inc.38